Mechanisms of zolpidem-induced long QT syndrome: Acute inhibition of recombinant hERG K+ channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells

British Journal of Pharmacology

Volumn 168, Issue 5, 2013, Pages 1215-1229

  Jehle, J ^a   Ficker, E ^b   Wan, X ^b   Deschenes, I ^b   Kisselbach, J ^a   Wiedmann, F ^a   Staudacher, I ^a   Schmidt, C ^a   Schweizer, P A ^a   Becker, R ^a   Katus, H A ^a   Thomas, D ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

action potential; hERG K+ channel; long QT syndrome; torsade de pointes; zolpidem

Indexed keywords

POTASSIUM CHANNEL HERG; RECOMBINANT PROTEIN; ZOLPIDEM;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARDIOTOXICITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; FEMALE; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PATCH CLAMP; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PLURIPOTENT STEM CELL; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; QT PROLONGATION; STEADY STATE; WESTERN BLOTTING;

ACTION POTENTIALS; ANIMALS; CELLS, CULTURED; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; HYPNOTICS AND SEDATIVES; INDUCED PLURIPOTENT STEM CELLS; LONG QT SYNDROME; MYOCYTES, CARDIAC; OOCYTES; POTASSIUM CHANNEL BLOCKERS; PYRIDINES; RECOMBINANT PROTEINS; XENOPUS LAEVIS;

EID: 84874268679     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12002     Document Type: Article

References (59)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. + current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res 58: 815-822.
3. Caspi O, Itzhaki I, Kehat I, Gepstein A, Arbel G, Huber I, et al. (2009). In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes. Stem Cells Dev 18: 161-172.
4. Cherubini A, Taddei GL, Crociani O, Paglierani M, Buccoliero AM, Fontana L, et al. (2000). HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer 83: 1722-1729.
5. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, et al. (1998). HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci U S A 95: 2979-2984.
6. De Haas SL, Schoemaker RC, van, Gerven JM, Hoever P, Cohen AF, Dingemanse J, (2010). Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 24: 1619-1629.
7. Dennis AT, Nassal D, Deschenes I, Thomas D, Ficker E, (2011). Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG. J Biol Chem 286: 34413-34425.
8. Drover DR, (2004). Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 43: 227-238.
9. Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. (2004). Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess 8: 1-125.
10. El Harchi A, Zhang YH, Hussein L, Dempsey CE, Hancox JC, (2012). Molecular determinants of hERG potassium channel inhibition by disopyramide. J Mol Cell Cardiol 52: 185-195.
11. Ficker E, Dennis AT, Wang L, Brown AM, (2003). Role of cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel HERG. Circ Res 92: e87-e100.
12. Ficker E, Kuryshev YA, Dennis AT, Obejero-Paz C, Wang L, Hawryluk P, et al. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66: 33-44.
13. 2P) potassium leak channels by the tyrosine kinase inhibitor genistein. Br J Pharmacol 154: 1680-1690.
14. Gong JH, Liu XJ, Shang BY, Chen SZ, Zhen YS, (2010). HERG K+ channel related chemosensitivity to sparfloxacin in colon cancer cells. Oncol Rep 23: 1747-1756.
15. Greenblatt DJ, Legangneux E, Harmatz JS, Weinling E, Freeman J, Rice K, et al. (2006). Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 46: 1469-1480.
16. Kr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes. J Pharmacol Exp Ther 321: 911-920.
17. Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W, (2003). Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98: 1371-1378.
18. Hausken AM, Furu K, Skurtveit S, Engeland A, Bramness JG, (2009). Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors. Eur J Clin Pharmacol 65: 295-301.
19. Hondeghem LM, (2008). Use and abuse of QT and TRIaD in cardiac safety research: importance of study design and conduct. Eur J Pharmacol 584: 1-9.
20. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, et al. (2011). Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471: 225-229.
21. Jehle J, Schweizer PA, Katus HA, Thomas D, (2011). Novel roles for hERG K(+) channels in cell proliferation and apoptosis. Cell Death Dis 2: e193.
22. Jones AW, Holmgren A, Kugelberg FC, (2007). Concentrations of scheduled prescription drugs in blood of impaired drivers: considerations for interpreting the results. Ther Drug Monit 29: 248-260.
23. Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W, (1999). Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol 359: 212-219.
24. Lacerda AE, Kramer J, Shen KZ, Thomas D, Brown AM, (2001). Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J 3 (Suppl. K): K23-K30.
25. Letsas KP, Filippatos GS, Kounas SP, Efremidis M, Sideris A, Kardaras F, (2006). QT interval prolongation and Torsades de Pointes in a patient receiving zolpidem and amiodarone. Cardiology 105: 146-147.
26. s protein in the sinoatrial node. J Am Heart Assoc 1: jah3-e000372.
27. Ma J, Guo L, Fiene SJ, Anson BD, Thomson JA, Kamp TJ, et al. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 301: H2006-H2017.
28. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
29. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC, (2000). A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 97: 12329-12333.
30. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, et al. (2010). Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363: 1397-1409.
31. Nicholson AN, Pascoe PA, (1986). Hypnotic activity of an imidazo-pyridine (zolpidem). Br J Clin Pharmacol 21: 205-211.
32. Obers S, Staudacher I, Ficker E, Dennis A, Koschny E, Erdal H, et al. (2010). Multiple mechanisms of hERG liability: K+ current inhibition, disruption of protein trafficking, and apoptosis induced by amoxapine. Naunyn Schmiedebergs Arch Pharmacol 381: 385-400.
33. Peng S, Lacerda AE, Kirsch GE, Brown AM, Bruening-Wright A, (2010). The action potential and comparative pharmacology of stem cell-derived human cardiomyocytes. J Pharmacol Toxicol Methods 61: 277-286.
34. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, et al. (2006). Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149: 481-489.
35. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
36. Roden D, (2008). Repolarization reserve: a moving target. Circulation 118: 981-982.
37. Salvà P, Costa J, (1995). Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 29: 142-153.
38. Sanguinetti MC, Tristani-Firouzi M, (2006). hERG potassium channels and cardiac arrhythmia. Nature 440: 463-469.
39. 2P3.1) K+ current inhibition by endothelin-1 is mediated by Rho kinase-dependent channel phosphorylation. Br J Pharmacol 165: 1467-1475.
40. + channels in neoplastic hematopoietic cells. J Biol Chem 277: 18528-18534.
41. Soucek R, Thomas D, Kelemen K, Bikou O, Seyler C, Voss F, et al. (2012). Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm 9: 265-272.
42. Staudacher I, Schweizer PA, Katus HA, Thomas D, (2010). hERG: protein trafficking and potential for drug side effects. Curr Opin Drug Discov Devel 13: 23-30.
43. Staudacher I, Wang L, Wan X, Obers S, Wenzel W, Tristram F, et al. (2011a). hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine. Naunyn Schmiedebergs Arch Pharmacol 383: 119-139.
44. 2P3.1 (TASK1) K+ leak channels. Br J Pharmacol 163: 1099-1110.
45. Takemasa H, Nagatomo T, Abe H, Kawakami K, Igarashi T, Tsuguri T, et al. (2007). Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol 153: 439-447.
46. Thomas D, Zhang W, Karle CA, Kathöfer S, Schöls W, Kübler W, et al. (1999). Deletion of protein kinase a phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J Biol Chem 274: 27457-27462.
47. Thomas D, Wendt-Nordahl G, Röckl K, Ficker E, Brown AM, Kiehn J, (2001). High affinity blockade of HERG human cardiac potassion channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther 297: 735-761.
48. Thomas D, Kiehn J, Katus HA, Karle CA, (2003). Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res 60: 235-241.
49. Thomas D, Gut B, Karsai S, Wimmer AB, Wu K, Wendt-Nordahl G, et al. (2004a). Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn Schmiedebergs Arch Pharmacol 368: 41-48.
50. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, et al. (2004b). Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol 369: 462-472.
51. Kr potassium channel as pharmacological target: structure, function, regulation, and clinical applications. Curr Pharm Des 12: 2271-2283.
52. Thomas D, Bloehs R, Koschny R, Ficker E, Sykora J, Kiehn J, et al. (2008). Doxazosin induces apoptosis of cells expressing hERG potassium channels. Eur J Pharmacol 579: 98-103.
53. Trappe K, Thomas D, Bikou O, Kelemen K, Lugenbiel P, Voss F, et al. (2012). Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3-a preclinical pilot study. Eur Heart J doi: 10.1093/eurheartj/ehr269.
54. Van der Heyden MAG, Smits ME, Vos MA, (2008). Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol 153: 406-409.
55. Viskin S, (1999). Long QT syndromes and torsade de pointes. Lancet 354: 1625-1633.
56. Wang H, Zhang Y, Cao L, Han H, Wang J, Yang B, et al. (2002). HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res 62: 4843-4848.
57. Wang L, Wible BA, Wan X, Ficker E, (2007). Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther 320: 525-534.
58. Zhang YH, Cheng H, Alexeenko VA, Dempsey CE, Hancox JC, (2010). Characterization of recombinant hERG K(+) channel inhibition by the active metabolite of amiodarone desethyl-amiodarone. J Electrocardiol 43: 440-448.
59. Zitron E, Kiesecker C, Scholz EP, Lück S, Bloehs R, Kathöfer S, et al. (2004). Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone. Naunyn Schmiedebergs Arch Pharmakol 370: 146-156.